Serum ICAM-1 concentrations following conventional dose consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell rescue.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86191
Title:
Serum ICAM-1 concentrations following conventional dose consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell rescue.
Authors:
Wang, X; Clowes, C; Duarte, R; Pu, Qingqiu
Abstract:
Serum concentrations of soluble ICAM-1 (sICAM-1) were studied in patients with acute myeloid leukemia (AML) after conventional dose consolidation chemotherapy and in AML and in breast cancer patients following high dose chemotherapy with autologous haematopoietic stem cell transplantation. Investigations were carried out at 3 phases following treatment; during the chemotherapy induced neutropenic phase (neutrophil counts <0.5x109/l); during early recovery (neutrophil counts 0.5x109/l-1.0x109/l); and at recovery from neutropenia (neutrophil count 1.0x109/l-2.5x109/l). Results showed a significant elevation of serum levels of sICAM-1, above normal, in both groups of patients during the neutropenic phase. A further increase of sICAM-1 was found in conventional dose consolidation chemotherapy treated AML patients during the post-neutropenia recovery phases. By contrast, patients who were treated with high dose chemotherapy plus autologous haematopoietic stem cell transplantation showed a normalisation of sICAM-1 concentration during the post-neutropenic recovery phases. These findings suggest that recovery of neutrophil function do not coincide with recovery of neutrophil count following intensive chemotherapy while rapid recovery of neutrophil function occurred among patients who received autologous haematopoietic stem cell support.
Affiliation:
School of Biological Science, The University of Manchester, UK.
Citation:
Serum ICAM-1 concentrations following conventional dose consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell rescue. 2000, 17 (3):591-5 Int. J. Oncol.
Journal:
International Journal of Oncology
Issue Date:
Sep-2000
URI:
http://hdl.handle.net/10541/86191
PubMed ID:
10938403
Type:
Article
Language:
en
ISSN:
1019-6439
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorWang, Xen
dc.contributor.authorClowes, Cen
dc.contributor.authorDuarte, Ren
dc.contributor.authorPu, Qingqiuen
dc.date.accessioned2009-11-13T15:53:16Z-
dc.date.available2009-11-13T15:53:16Z-
dc.date.issued2000-09-
dc.identifier.citationSerum ICAM-1 concentrations following conventional dose consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell rescue. 2000, 17 (3):591-5 Int. J. Oncol.en
dc.identifier.issn1019-6439-
dc.identifier.pmid10938403-
dc.identifier.urihttp://hdl.handle.net/10541/86191-
dc.description.abstractSerum concentrations of soluble ICAM-1 (sICAM-1) were studied in patients with acute myeloid leukemia (AML) after conventional dose consolidation chemotherapy and in AML and in breast cancer patients following high dose chemotherapy with autologous haematopoietic stem cell transplantation. Investigations were carried out at 3 phases following treatment; during the chemotherapy induced neutropenic phase (neutrophil counts <0.5x109/l); during early recovery (neutrophil counts 0.5x109/l-1.0x109/l); and at recovery from neutropenia (neutrophil count 1.0x109/l-2.5x109/l). Results showed a significant elevation of serum levels of sICAM-1, above normal, in both groups of patients during the neutropenic phase. A further increase of sICAM-1 was found in conventional dose consolidation chemotherapy treated AML patients during the post-neutropenia recovery phases. By contrast, patients who were treated with high dose chemotherapy plus autologous haematopoietic stem cell transplantation showed a normalisation of sICAM-1 concentration during the post-neutropenic recovery phases. These findings suggest that recovery of neutrophil function do not coincide with recovery of neutrophil count following intensive chemotherapy while rapid recovery of neutrophil function occurred among patients who received autologous haematopoietic stem cell support.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectHaematapoietic Stem Cell Transplantationen
dc.subjectMyeloid Leukaemiaen
dc.subjectCancer Proteinsen
dc.subject.meshAcute Disease-
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBiological Markers-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshCytarabine-
dc.subject.meshEtoposide-
dc.subject.meshFemale-
dc.subject.meshFilgrastim-
dc.subject.meshHematopoietic Stem Cell Transplantation-
dc.subject.meshHumans-
dc.subject.meshIdarubicin-
dc.subject.meshIntercellular Adhesion Molecule-1-
dc.subject.meshLeukemia, Myeloid-
dc.subject.meshLeukocyte Count-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Proteins-
dc.subject.meshNeutropenia-
dc.subject.meshNeutrophils-
dc.subject.meshSolubility-
dc.titleSerum ICAM-1 concentrations following conventional dose consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell rescue.en
dc.typeArticleen
dc.contributor.departmentSchool of Biological Science, The University of Manchester, UK.en
dc.identifier.journalInternational Journal of Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.